Literature DB >> 11855542

Effect of rebamipide in treatment of Helicobacter pylori-associated duodenal ulcer: attenuation of chemokine expression and nitrosative damage.

K W Choi1, Y C Lee, I S Chung, J J Lee, M H Chung, N Y Kim, S W Kim, J G Kim, I H Roe, S W Lee, H Y Jung, M G Choi, K B Hahm, W S Hong, J H Kim.   

Abstract

Production of cytokines along with increased activity of nitric oxide synthase has been implicated as one of the contributing mechanisms of Helicobacter pylori-mediated gastroduodenal diseases. We aimed to evaluate the effect of rebamipide in treating Helicobacter pylori-associated duodenal ulcers in terms of cytokine production and nitrosative damage of the gastric mucosa. In patients with duodenal ulcers, rebamipide or placebo were given randomly after eradication. Mucosal cytokine production was measured by enzyme linked immunoassay, and nitrotyrosine immunoexpression was measured by immunohistochemistry. The inflammatory activity and degree of neutrophil infiltration were graded accordingly. The mucosal production of RANTES, interleukin-8, and TNF-alpha showed a significant decrease after eradication in patients with rebamipide after-treatment. The nitrotyrosine immunoreactivity of gastric epithelium was significantly decreased in the rebamipide group. Rebamipide treatment after eradication resulted in a significant reduction in chemokine production along with nitrotyrosine immunoexpression in Helicobacter pylori-associated duodenal ulcers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11855542     DOI: 10.1023/a:1013753602149

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  31 in total

1.  The Sydney System: a new classification of gastritis. Introduction.

Authors:  J J Misiewicz
Journal:  J Gastroenterol Hepatol       Date:  1991 May-Jun       Impact factor: 4.029

2.  Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment.

Authors:  E A Rauws; W Langenberg; H J Houthoff; H C Zanen; G N Tytgat
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

3.  Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa.

Authors:  Y Yamaoka; M Kita; T Kodama; N Sawai; J Imanishi
Journal:  Gastroenterology       Date:  1996-06       Impact factor: 22.682

Review 4.  Interleukin-8 and related chemotactic cytokines--CXC and CC chemokines.

Authors:  M Baggiolini; B Dewald; B Moser
Journal:  Adv Immunol       Date:  1994       Impact factor: 3.543

5.  Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES.

Authors:  T J Schall; K Bacon; K J Toy; D V Goeddel
Journal:  Nature       Date:  1990-10-18       Impact factor: 49.962

6.  Reduced oxidative and nitrosative damage in murine experimental colitis in the absence of inducible nitric oxide synthase.

Authors:  B Zingarelli; C Szabó; A L Salzman
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

Review 7.  Enhanced T-helper 2 lymphocyte responses: immune mechanism of Helicobacter pylori infection.

Authors:  X G Fan; J Yakoob; X J Fan; P W Keeling
Journal:  Ir J Med Sci       Date:  1996 Jan-Mar       Impact factor: 1.568

8.  Chemokines in the gastric mucosa in Helicobacter pylori infection.

Authors:  Y Yamaoka; M Kita; T Kodama; N Sawai; T Tanahashi; K Kashima; J Imanishi
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

Review 9.  Role of cytokines in pathogenesis of Helicobacter pylori-induced mucosal damage.

Authors:  J E Crabtree
Journal:  Dig Dis Sci       Date:  1998-09       Impact factor: 3.199

10.  Enhanced gastric nitric oxide synthase activity in duodenal ulcer patients.

Authors:  D Rachmilewitz; F Karmeli; R Eliakim; R Stalnikowicz; Z Ackerman; G Amir; J S Stamler
Journal:  Gut       Date:  1994-10       Impact factor: 23.059

View more
  2 in total

1.  Anti-inflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis: a randomized sucralfate-controlled multicenter trial in China-STARS study.

Authors:  Yiqi Du; Zhaoshen Li; Xianbao Zhan; Jie Chen; Jun Gao; Yanfang Gong; Jianlin Ren; Liping He; Zhijian Zhang; Xiaozhong Guo; Jianshen Wu; Zibin Tian; Ruihua Shi; Bo Jiang; Dianchun Fang; Youming Li
Journal:  Dig Dis Sci       Date:  2008-02-21       Impact factor: 3.199

2.  Gastric Helicobacter infection inhibits development of oral tolerance to food antigens in mice.

Authors:  Tamara Matysiak-Budnik; Guillaume van Niel; Francis Mégraud; Kathryn Mayo; Claudia Bevilacqua; Valérie Gaboriau-Routhiau; Marie-Christiane Moreau; Martine Heyman
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.